Kinnate Biopharma Inc. (KNTE) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 117 transactions totaling $79.8M, demonstrating a bullish sentiment with $79.8M in net insider flow. The most recent transaction on Apr 3, 2024 involved a transaction of 9,671,643 shares valued at $0.
No significant insider buying has been recorded for KNTE in the recent period.
No significant insider selling has been recorded for KNTE in the recent period.
Based on recent SEC filings, insider sentiment for KNTE is bullish with an Insider Alignment Score of 100/100 and a net flow of $79.8M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Kinnate Biopharma Inc. (KNTE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading KNTE stock, having executed 117 transactions in the past 90 days. The most active insider is James B. Tananbaum (Executive), who has made 12 transactions totaling $25.0M.
Get notified when executives and directors at KNTE file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | Opportunity Fund V, L.p. Foresite Capital | Executive | Disposition | 9,671,643 | $N/A | $0 | |
| Apr 3, 2024 | Opportunity Fund V, L.p. Foresite Capital | Executive | Disposition | 520,711 | $N/A | $0 | |
| Apr 3, 2024 | Opportunity Fund V, L.p. Foresite Capital | Executive | Disposition | 3,525,957 | $N/A | $0 | |
| Apr 3, 2024 | Gp Iv, L.p. Orbimed Asia | Executive | Disposition | 84,599 | $N/A | $0 | |
| Apr 3, 2024 | Gp Iv, L.p. Orbimed Asia | Executive | Disposition | 450,000 | $N/A | $0 | |
| Apr 3, 2024 | Gp Iv, L.p. Orbimed Asia | Executive | Disposition | 1,368,338 | $N/A | $0 | |
| Apr 3, 2024 | Gp Iv, L.p. Orbimed Asia | Executive | Disposition | 1,368,339 | $N/A | $0 | |
| Apr 3, 2024 | Gp Iv, L.p. Orbimed Asia | Executive | Disposition | 4,738,453 | $N/A | $0 | |
| Apr 3, 2024 | L. Gordon Carl | Executive | Disposition | 1,368,339 | $N/A | $0 | |
| Apr 3, 2024 | L. Gordon Carl | Executive | Disposition | 450,000 | $N/A | $0 | |
| Apr 3, 2024 | L. Gordon Carl | Executive | Disposition | 84,599 | $N/A | $0 | |
| Apr 3, 2024 | L. Gordon Carl | Executive | Disposition | 1,368,338 | $N/A | $0 | |
| Apr 3, 2024 | L. Gordon Carl | Executive | Disposition | 4,738,453 | $N/A | $0 | |
| Apr 3, 2024 | A. Meltz Mark | Executive | Disposition | 27,578 | $N/A | $0 | |
| Apr 3, 2024 | T. Flaherty Keith | Executive | Disposition | 66,377 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 49 | $79.8M | 79.9% |
Award(A) | 10 | $20.0M | 20.0% |
Payment(F) | 18 | $64.7K | 0.1% |
Disposition(D) | 20 | $0 | 0.0% |
Other(J) | 2 | $0 | 0.0% |
Conversion(C) | 18 | $0 | 0.0% |
Insiders at Kinnate Biopharma Inc. are accumulating shares at an accelerated pace. With 14 insiders making 117 transactions totaling $79.8M in purchases versus $0 in sales, the net buying activity of $79.8M signals strong executive confidence. James B. Tananbaum (Executive) leads the buying activity with $25.0M in transactions across all time.